|Awarded On||September 14, 2022|
|Title||Developing a novel optogenetic recombinase system to study and target metastatic cancer|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Ravikanth Maddipati|
|Cancer Sites||Colorectal, Gallbladder, Liver and Intrahepatic Bile Duct, Pancreas|
*Pending contract negotiation
Metastasis is the major cause of death in most cancers. Metastases result from cancer cells that have migrated away from the primary tumor and spread to other organs. This requires tumor cells to adapt by acquiring properties, unique from the primary tumor, to grow in their new surroundings. Thus, current therapies designed to treat primary tumors have limited efficacy in metastasis. A major barrier to understanding and targeting metastasis specific adaptations is the lack of model systems that capture the metastatic behaviors of human tumors. A powerful method to study tumor biology are genetically engineered mouse models (GEMMs). GEMMs rely on genetically encoded Cre-recombinase proteins t...